Stephen L. Kopecky, M.D.

Interests include cardiovascular clinical trials primarily in coronary artery disease and acute coronary syndromes.

My research involves protocol development, coordination, management and analysis of multicenter randomized cardiovascular trials. Our clinical trial group, MPACT (Mayo Physician Alliance for Clinical Trials), is a network of 700 investigators. We try to ask and answer clinically relevant questions about cardiovascular disease.

Prior studies include Festival (F2G in Elevated ST Infarction Evaluation) and ADMIRE (AMP 579 Delivery for Myocardial Infarction Reduction), aimed at infarct size reduction. Currently we are studying AMP579, a multi-receptor adenosine agonist, in an AMI population treated with thrombolysis.

MPACT CV

Projects include the following:

1. Immunopathways in Acute Coronary Syndromes (T-cell Study).
2. Role of the Immune System in the Pathogenesis of Unstable Angina in the Hispanic Population (Maricopa Study).
3. ADMIRE (AMP 579 Delivery for Myocardial Infarction Reduction). A Randomized, Double- Blind Placebo-Controlled Dose-Ranging Study to Determine the Safety and Efficacy of AMP579 in Patients with Acute myocardial Infarction Treated with Primary Angioplasty.
4. ACTION (Anticoagulation Consortium to Improve Outcomes Nationally). A registry of 10,000 patients in 300 anticoagulation clinics to follow outcomes of patients with atrial fibrillation.
5. SWISS (Siblings With Ischemic Stroke Study).